Outlicensing Offers Benefits to Japanese Pharma – Aveo CEO
This article was originally published in PharmAsia News
Executive Summary
By outlicensing early-stage compounds, Japanese pharma can gain benefits beyond receiving licensing fees, including de-risking Japanese development, according to a U.S. biotech CEO